The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

To make a type 2 diabetes diagnosis, doctors can use several different blood tests. You’ll typically need to be tested at least twice to confirm a diagnosis. Most people are tested for diabetes ...

Chrissy Teigen’s midnight snacks rival the menus of some restaurants. The mogul, model and mother of four appeared on TODAY March 12 to talk about adding another title to her resume: podcast hos ...

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma's obesity drug candidate.

Roche has entered an exclusive collaboration and licensing agreement with Danish obesity drug maker Zealand Pharma to co-develop petrelintide as an obesity therapy drug, the Swiss company said on ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF – Research Report) and Q32 Bio (QTTB – Research Report). Effectively ...

Roche shares gained 5.5%. Zealand is testing petrelintide, opens new tab in overweight or obese individuals without type 2 diabetes in a mid-stage study. Petrelintide belongs to a class of drugs ...

LONDON — Looking to expand its obesity offerings, Roche on Wednesday said it had partnered with Zealand Pharma to license an experimental weight loss drug for $1.65 billion in upfront cash.